BridgeBio Pharma Inc
NASDAQ:BBIO

Watchlist Manager
BridgeBio Pharma Inc Logo
BridgeBio Pharma Inc
NASDAQ:BBIO
Watchlist
Price: 39.58 USD 2.49%
Market Cap: 7.5B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

BBIO Price Targets Summary
BridgeBio Pharma Inc

Wall Street analysts forecast BBIO stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BBIO is 61.58 USD with a low forecast of 37.37 USD and a high forecast of 99.75 USD.

BBIO Lowest Forecast
Wall Street Target
37.37 USD
6% Downside
BBIO Average Forecast
Wall Street Target
61.58 USD
56% Upside
BBIO Highest Forecast
Wall Street Target
99.75 USD
152% Upside
Lowest
Price Target
37.37 USD
6% Downside
Average
Price Target
61.58 USD
56% Upside
Highest
Price Target
99.75 USD
152% Upside
BridgeBio Pharma Inc Competitors:
Price Targets
ANAB
AnaptysBio Inc
87% Upside
6160
Beigene Ltd
17% Upside
GRAL
Grail Inc
16% Downside
B
BAVA
Bavarian Nordic A/S
57% Upside
ANAB
AnaptysBio Inc
87% Upside
6160
Beigene Ltd
17% Upside
GRAL
Grail Inc
16% Downside
B
BAVA
Bavarian Nordic A/S
57% Upside
002007
Hualan Biological Engineering Inc
20% Upside
NTLA
Intellia Therapeutics Inc
380% Upside
CDNA
CareDx Inc
50% Upside
ITOS
Iteos Therapeutics Inc
18% Upside

Revenue
Forecast

Revenue Estimate
BridgeBio Pharma Inc

The compound annual growth rate of BridgeBio Pharma Inc's revenue for the next 3 years is 78%.

N/A
Past Growth
78%
Estimated Growth
Estimates Accuracy
-9%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
BridgeBio Pharma Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
BridgeBio Pharma Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-23%
Average Miss
What are analyst estimates?

See Also

Summary
BBIO intrinsic value, competitors valuation, and company profile.
DCF Valuation
BBIO stock valuation using Discount Cash Flow valuation method.
Relative Valuation
BBIO stock valuation using valuation multiples.
Wall Street Estimates
BBIO price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
BBIO stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is BBIO's stock price target?
Price Target
61.58 USD

According to Wall Street analysts, the average 1-year price target for BBIO is 61.58 USD with a low forecast of 37.37 USD and a high forecast of 99.75 USD.

What is BridgeBio Pharma Inc's Revenue forecast?
Projected CAGR
78%

The compound annual growth rate of BridgeBio Pharma Inc's revenue for the next 3 years is 78%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 260,600+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.